CGAS and neoplasm: Combination therapy targeting cGAS‐STING has made certain progress in both preclinical and clinical trials, but the development of optimal treatment regimens remains challenging.[98] Nevertheless, the findings from this study are encouraging, as they provide novel insights into the NK resistance in CTCs and may lead to new strategies to eliminate CTCs and prevent tumor metastasis.